ASCO ascent

Gainers, decliners in the wake of 2018’s ASCO conference

Kinase inhibitor company Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH) and cancer assay developer Genomic Health Inc. (NASDAQ:GHDX) each hit all-time highs in the wake of data readouts at the American Society of Clinical Oncology meeting in Chicago.

Deciphera gained 36% during the week after it reported updated data from a Phase I trial in patients with gastrointestinal stromal tumors (GIST) (see “ASCO 2018 Movers”).

The data showed Deciphera’s DCC-2618 led to response rates that compare favorably with approved therapies in some

Read the full 772 word article

User Sign In